[go: up one dir, main page]

DE60237425D1 - PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung - Google Patents

PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung

Info

Publication number
DE60237425D1
DE60237425D1 DE60237425T DE60237425T DE60237425D1 DE 60237425 D1 DE60237425 D1 DE 60237425D1 DE 60237425 T DE60237425 T DE 60237425T DE 60237425 T DE60237425 T DE 60237425T DE 60237425 D1 DE60237425 D1 DE 60237425D1
Authority
DE
Germany
Prior art keywords
alkyl
group
cycloalkyl
optionally substituted
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237425T
Other languages
English (en)
Inventor
Daniela Moravcova
Libor Havlicek
Vladimir Krystof
Rene Lenobel
Miroslav Strnad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Experimental Botany Academy CAS
Palacky University Olomouc
Original Assignee
Institute of Experimental Botany Academy CAS
Palacky University Olomouc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Experimental Botany Academy CAS, Palacky University Olomouc filed Critical Institute of Experimental Botany Academy CAS
Application granted granted Critical
Publication of DE60237425D1 publication Critical patent/DE60237425D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
DE60237425T 2002-03-28 2002-03-28 PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung Expired - Lifetime DE60237425D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02007163A EP1348707B1 (de) 2002-03-28 2002-03-28 Pyrazolo[4,3-d]pyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung

Publications (1)

Publication Number Publication Date
DE60237425D1 true DE60237425D1 (de) 2010-10-07

Family

ID=27798825

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237425T Expired - Lifetime DE60237425D1 (de) 2002-03-28 2002-03-28 PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung

Country Status (9)

Country Link
US (1) US7745450B2 (de)
EP (1) EP1348707B1 (de)
JP (1) JP2005527565A (de)
AT (1) ATE478872T1 (de)
AU (1) AU2003226731B2 (de)
CA (1) CA2480409C (de)
DE (1) DE60237425D1 (de)
DK (1) DK1348707T3 (de)
WO (1) WO2003082872A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
AU2004234158B2 (en) * 2003-04-29 2010-01-28 Pfizer Inc. 5,7-diaminopyrazolo[4,3-D]pyrimidines useful in the treatment of hypertension
JP4681548B2 (ja) 2003-07-22 2011-05-11 アステックス・セラピューティクス・リミテッド ３，４−ジ置換１ｈ−ピラゾール化合物および、そのサイクリン依存性キナーゼ（ｃｄｋ）およびグリコーゲン・シンセターゼ・キナーゼ−３（ｇｓｋ−３）調節剤としての使用
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
RU2006126791A (ru) * 2003-12-23 2008-01-27 Новартис АГ (CH) Бициклические гетероциклические ингибиторы р-38 киназы
WO2005097799A1 (en) 2004-04-07 2005-10-20 Pfizer Limited Pyrazolo`4,3-d! pyrimidines
RU2389731C2 (ru) * 2004-06-02 2010-05-20 Такеда Фармасьютикал Компани Лимитед Конденсированное гетероциклическое соединение
ATE517901T1 (de) 2004-09-06 2011-08-15 Bayer Schering Pharma Ag Pyrazolopyrimidine als hemmer der proteinkinase b (akt)
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
RU2425677C2 (ru) * 2005-01-21 2011-08-10 Астекс Терапьютикс Лимитед Соединения, предназначенные для использования в фармацевтике
MX2007013215A (es) * 2005-05-12 2007-12-12 Pfizer Formas cristalinas anhidras de la n-[1-(2-etoxietil)-5-(n-etil-n- metilamino)-7-(4-metilpiridin-2-il-amino)-1h-pirazolo[4,3-d] pirimidina -3-carbonil] metanosulfonamida.
EP1915377A1 (de) 2005-07-22 2008-04-30 Sunesis Pharmaceuticals, Inc. Als aurorakinaseinhibitoren geeignete pyrazolpyrimidine
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
FR2899107B1 (fr) 2006-03-30 2008-06-13 Neurokin Entpr Unipersonnelle Utilisation de la (s)-roscovitine pour la fabrication d'un medicament
RU2009126576A (ru) 2006-12-12 2011-01-20 Такеда Фармасьютикал Компани Лимитед (Jp) Конденсированное гетероциклическое соединение
US20090099195A1 (en) * 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
CN102272133A (zh) 2008-11-06 2011-12-07 阿斯利康(瑞典)有限公司 淀粉样β的调节剂
CZ2009358A3 (cs) * 2009-06-03 2010-12-15 C3 Bio Gmbh 5,7-Disubstituované 3-isopropylpyrazolo[4,3-d]pyrimidiny pro použití jako lécivo a farmaceutické prípravky tyto látky obsahující
CZ302711B6 (cs) 2009-06-03 2011-09-14 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-hydroxybenzylamino)purinu, jejich použití jako léciva a farmaceutické prípravky tyto slouceniny obsahující
TWI606049B (zh) * 2011-04-21 2017-11-21 原真股份有限公司 新穎激酶抑制劑
LT2734186T (lt) 2011-07-22 2018-12-10 Glaxosmithkline Llc Kompozicija
AR090650A1 (es) * 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
WO2014031815A1 (en) 2012-08-24 2014-02-27 Glaxosmithkline Llc Pyrazolopyrimidine compounds
WO2014060112A1 (en) * 2012-10-19 2014-04-24 Origenis Gmbh Pyrazolo[4,3-d]pyrimidines as kinase inhibitors
RS56233B1 (sr) 2012-11-20 2017-11-30 Glaxosmithkline Llc Nova jedinjenja
AU2013348216B2 (en) 2012-11-20 2016-10-13 Glaxosmithkline Llc Novel compounds
WO2014081644A1 (en) 2012-11-20 2014-05-30 Glaxosmithkline Llc Novel compounds
CN103405439B (zh) * 2013-08-02 2014-12-31 上海市第十人民医院 嘧啶类化合物在制备真菌药物的应用
CA2984949A1 (en) * 2015-03-16 2016-09-22 Monash University Treatment of skin conditions
CZ307147B6 (cs) * 2015-05-14 2018-02-07 Ústav experimentální botaniky AV ČR, v. v. i. 5-Substituované 7-[4-(2-pyridyl)fenylmethylamino]-3-isopropylpyrazolo[4,3-d]pyrimidiny, jejich použití jako léčiva, a farmaceutické přípravky
EP3528813B1 (de) 2016-09-30 2025-04-16 ABS Development 1, Inc. P2x3- und/oder p2x2/3-verbindungen und verfahren
CZ308484B6 (cs) * 2018-02-05 2020-09-16 Univerzita PalackĂ©ho v Olomouci 5-Alkylthio-7-[(4-arylbenzyl)amino]-1(2)H-pyrazolo[4,3-d]pyrimidiny pro léčení lymfomů
EP3797776B1 (de) * 2019-09-30 2025-07-23 Universitätsmedizin Mainz Cdk4/6-hemmer zur behandlung von psoriasis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988338A (en) * 1974-04-24 1976-10-26 Wisconsin Alumni Research Foundation 4-Substituted amino-2-substituted thio-pyrrolo-[2,3-d]pyrimidine derivatives
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5276143A (en) 1990-12-21 1994-01-04 E. I. Du Pont De Nemours And Company Dideoxyfructonucleosides and deoxyfructonucleotides
US5801015A (en) 1995-06-05 1998-09-01 Mitotix, Inc. Nucleic acid encoding a Candida cell cycle regulatory protein, TYP1 polypeptide
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
ES2200039T3 (es) * 1995-12-08 2004-03-01 Pfizer Inc. Derivados heterociclicos sustituidos como antagonistas de crf.
TR199900389T2 (xx) * 1996-08-28 2000-06-21 Pfizer Inc. �kame edilmi� 6,5-hetero-bisiklik t�revleri.
US5723608A (en) * 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
KR100441229B1 (ko) * 1997-04-25 2004-07-22 화이자 인코포레이티드 타입 5 시클릭 구아노신 3',5'-모노포스페이트 포스포디에스테라제(ｃＧＭＰ ＰＤＥ5)를 억제하는 성기능 장애 치료용 피라졸로피리미디논
US5985848A (en) * 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
HUP0102543A3 (en) * 1998-04-20 2002-01-28 Pfizer Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction and medicaments containing them
JP2002528456A (ja) * 1998-10-23 2002-09-03 ファイザー・インク 性的機能障害の処置のためのピラゾロピリミジノン系ｃＧＭＰ阻害薬
AU1888800A (en) * 1999-09-13 2001-04-17 Cipla Limited A novel process for the synthesis of sildenafil citrate
AU779761C (en) * 1999-10-12 2005-09-22 Lilly Icos Llc Medicament for treatment of neuropathies
DE10060388A1 (de) * 2000-12-05 2002-06-06 Merck Patent Gmbh Verwendung von Pyrazolo [4,3-d]pyrimidinen
HUP0303315A2 (hu) * 2000-12-19 2004-01-28 Merck Patent Gmbh. Pirazolo [4,3-d] pirimidineket és trombózisellenes szereket, kalcium antagonistákat, prosztaglandinokat vagy prosztaglandinszármazékokat tartalmazó gyógyszerkészítmények
GB0106661D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
PL370599A1 (en) * 2001-11-02 2005-05-30 Pfizer Products Inc. Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
US20030195205A1 (en) * 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders

Also Published As

Publication number Publication date
CA2480409A1 (en) 2003-10-09
DK1348707T3 (da) 2010-12-13
JP2005527565A (ja) 2005-09-15
WO2003082872A1 (en) 2003-10-09
US7745450B2 (en) 2010-06-29
ATE478872T1 (de) 2010-09-15
CA2480409C (en) 2010-06-22
AU2003226731B2 (en) 2008-05-22
AU2003226731A1 (en) 2003-10-13
US20050080097A1 (en) 2005-04-14
EP1348707A1 (de) 2003-10-01
EP1348707B1 (de) 2010-08-25

Similar Documents

Publication Publication Date Title
DE60237425D1 (de) PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
CA2184919A1 (en) New Piperazine Derivatives and Methods for the Preparation Thereof and Compositions Containing the Same
BG107120A (bg) Нови бавнодействащи бетамиметици, метод за тяхното получаване и приложението им като лекарствени средства
CA2368413A1 (en) Derivatives of pyrimido[6,1-a]isoquinolin-4-one
CA2337041A1 (en) Aminomethylcarboxylic acid derivatives
DE69528437D1 (de) Substituierte azaindolylidenderivate und verfahren zu ihrer herstellung
HUP0301671A2 (hu) 4-Fenil-piridin-származékok, mint neurokinin-1-receptor antagonisták, eljárás az előállításukra és alkalmazásuk
WO2003076458A3 (en) Selective dipeptide inhibitors of kallikrein
HUP0100615A2 (hu) Szubsztituált 2-(2,6-dioxo-3-fluoro-piperidin-3-il)-izoindolinok és ezek alkalmazása TNFalfa-szint csökkentésére
WO2005092858A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
PT1159279E (pt) 4-oxo-4,7-di-hidrotieno¬2,3-b|piridino-5-carboxamidas como agentes antivirais
JP2006502119A5 (de)
ATE266013T1 (de) 1-phenyl-4-benzylpiperazine: spezifische liganden für den dopamin rezeptor (d4)
TW368501B (en) 7-(2-aminoethyl)-benzothiazolones
TW235297B (de)
JP2005538111A5 (de)
JP2001525394A5 (de)
RU2006101824A (ru) 6-ариламино-5-циано-4-пиримидионы
EP1857459A3 (de) Pyrazolopyrimidinverbindung und Verfahren zu ihrer Herstellung
CA2213080A1 (en) 1-aryl-2-acylamino-ethane compounds and their use as neurokinin especially neurokinin 1 antagonists
EP2289888A3 (de) Epoxidcarboxylsäureamide, Azide und Aminoalkohole sowie Verfahren zur Herstellung von Alpha-Ketoamiden damit
EP1465488A4 (de) Arylamine als hemmer der bindung von chemokinen an us28
ATE53032T1 (de) 2-thiazolylimidazo(1,2-a)pyrimidine und ihre salze, verfahren zu ihrer herstellung, ihre anwendung als arzneimittel und diese enthaltende zubereitungen.
RU2004107847A (ru) Изоксазолпиридиноны и их применение в лечении болезни паркинсона
ATE133938T1 (de) Indan-1,3-dion und indan-1,2,3-trionderivate, verfahren zu ihrer herstellung und ihre therapeutische verwendung